Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Alveolar soft part sarcoma; Chondrosarcoma; Chordoma; CNS cancer; Extranodal NK-T-cell lymphoma; Germ cell cancer; Haemangiosarcoma; Lymphoma; Myxoid liposarcoma; Neuroendocrine tumours; Ovarian cancer; Rhabdoid tumour; Sarcoma; Soft tissue sarcoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms AcSe
- 19 Jan 2024 Status changed from active, no longer recruiting to completed.
- 07 Jul 2023 Results (n=98) assessing the activity of pembrolizumab in rare and ultra-rare sarcomas published in the Lancet Oncology
- 06 Feb 2023 Planned End Date changed from 1 Dec 2023 to 26 Dec 2023.